Latest Regulatory Issues News

360 Capital REIT reported a 63.2% rise in statutory profit to $3.1 million for H1 2026, maintaining distributions and expanding its portfolio with a $10 million Sydney apartment block investment.

Australian Dairy Nutritionals reported a 152% surge in nutritional powder sales despite regulatory hurdles in Vietnam, while expanding its Future brand footprint across China.

Sarama Resources Ltd reported a $1.9 million loss for the first nine months of 2025 while securing A$2.7 million in equity funding and advancing a $242 million arbitration claim against Burkina Faso over mining permit expropriation.

The Treasurer has expressed preliminary concerns that Cosette Pharmaceuticals’ proposed acquisition of Mayne Pharma could harm Australia’s economy, citing plans to close a key Adelaide manufacturing site. Mayne Pharma disputes these claims and urges a resolution before the scheme deadline.

Advance Zintek reports a robust 26.83% revenue increase in Q1 FY26, driven by strong growth across North America, Australia, and Europe, despite regulatory hurdles impacting zinc oxide sales in Australia.

La Trobe Financial confirms the resolution of regulatory issues as ASIC lifts the Interim Stop Order on its 12 Month Term Account, restoring investor confidence.

Kali Metals Limited has successfully completed a placement raising approximately A$1.2 million through the issuance of new shares at A$0.14 each, reinforcing its capital position amid ongoing exploration efforts.

WAM Strategic Value reported a near 50% drop in net profit for FY2025 but maintained its fully franked dividend, supported by an 8.6% portfolio gain that outperformed market downturns.

WAM Global Limited reported a robust 39.8% increase in net profit for FY2025, driven by a 19.4% growth in its investment portfolio and declared a fully franked full year dividend of 17 cents per share. The company’s diversified global holdings and disciplined investment approach underpin its strong shareholder returns.

St Barbara Limited reports steady gold production and strong financials while progressing the Simberi Expansion Project, though a PNG tax dispute delays funding decisions.

Kore Potash has signed non-binding term sheets with OWI-RAMS for a $2.2 billion funding package to develop its flagship Kola Potash Project in the Republic of Congo, combining senior secured finance and royalty-based funding under Shariah principles.

Mayne Pharma rebuffs Cosette's claim of a material adverse change in their merger scheme and secures FDA clearance on regulatory concerns, maintaining its commitment to the deal's completion.